[시장보고서]호산구성 식도염 시장 : 약제 클래스별, 유통 채널별, 지역별-2025-2032년 시장 규모, 점유율, 전망, 기회 분석

호산구성 식도염 시장 : 약제 클래스별, 유통 채널별, 지역별-2025-2032년 시장 규모, 점유율, 전망, 기회 분석

Eosinophilic Esophagitis Market, by Drug Class, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2025 - 2032

상품코드 : 1699448

리서치사 : Coherent Market Insights

발행일 : 2025년 03월

페이지 정보 : 영문

라이선스 & 가격 (부가세 별도)

US $ 4,500

￦ 6,286,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,000

￦ 9,778,000

PDF (Multi User License)

PDF 보고서를 동일 사업장에서 7명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000

￦ 13,969,000

PDF (Enterprise User License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

세계의 호산구성 식도염 시장은 2025년에 2억 3,910만 달러, 2032년에는 17억 9,740만 달러에 이를 것으로 예측되며, 2025년부터 2032년까지 연평균 복합 성장률(CAGR) 33.4%로 성장할 것으로 예측됩니다.

보고 범위		보고서 세부정보
기준연도	2024년	2025년 시장 규모	2억 3,910만 달러
실적 데이터	2020-2024년	예측 기간	2025-2032년
예측 기간 : 2025-2032년 CAGR :	33.40%	2032년 가치 예측	17억 9,740만 달러

그림. 호산구성 식도염 시장 점유율 지역별(%) 2025년

호산구성 식도염은 만성 질환이며 스테로이드와 양성자 펌프 억제제와 같은 산 억제제의 도움으로 치료됩니다. 스테로이드는 염증을 억제하는데 도움이 됩니다. 흡입제 또는 액체로 투여됩니다. 경구 스테로이드는 심한 삼키는 장애와 체중 감소가있는 경우 처방됩니다. 양성자 펌프 억제제는 역류 증상을 개선하고 염증을 억제합니다.

시장 역학

호산구성 식도염에 대한 치료 의식 증가는 치료제 수요 증가로 이어집니다. Sanofi S.A.는 듀픽센트(듀필마브)의 제3상 임상시험에 임하고 있으며, 2024년까지 완료될 것으로 예상되고 있습니다. Takeda Pharmaceutical Company Limited는 호산구성 식도염 치료제 TAK-721(부데소니드 경구 현탁액)에 대해 미국 식품의약국(FDA)으로부터 심사완료보고 통지를 받았습니다. Pharmaceuticals, Inc.가 연구하고 있었습니다. 또한, 호산구성 식도염의 유병률 증가가 시장의 성장을 뒷받침할 가능성이 높습니다.

본 조사의 주요 특징

본 보고서에서는 2024년을 기준연도로 한 예측기간(2025-2032년)에 있어서의 세계의 호산구성 식도염 시장 규모를 상세하게 분석했습니다.
다른 부문에 걸친 잠재적인 수익 기회를 해명해, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
또한 시장 성장 촉진요인, 억제요인, 기회, 신제품의 상시나 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 고찰도 제공합니다.
세계의 호산구성 식도염 시장에 있어서의 주요 기업 프로파일을, 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 업적, 전략 등의 파라미터에 근거해 제공합니다.
이 보고서의 통찰은 마케팅 담당자와 기업 경영진이 향후 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전술에 대한 정보를 바탕으로 의사 결정을 할 수 있게 합니다.
세계의 호산구성 식도염 시장 보고서는 투자자, 공급자, 제품 제조업체, 판매업자, 신규 참가자, 재무 애널리스트 등, 이 업계의 다양한 이해 관계자에 대응하고 있습니다.
이해관계자는 세계의 호산구성 식도염 시장을 분석할 때 사용되는 다양한 전략 매트릭스를 통해 의사 결정이 용이해집니다.

히트맵 분석
시장 점유율 분석
- Ellodi Pharmaceuticals.
- EsoCap AG
- GlaxoSmithKline plc.
- Teva Pharmaceutical Industries Ltd
- Cipla Limited
- Sun Pharmaceutical Industries Limited
- AstraZeneca Plc
- Sanofi SA
- Arena Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Revolo Biotherapeutics
- Allakos Inc.
- Bristol-Myers Squibb Co
- Calypso Biotech
- DBV Technologies
- Landos Biopharma, Inc.
- Glenmark Pharmaceuticals
- Alkem Laboratories Ltd.
- Quorum Innovations LLC
- Falk Pharma GmbH

제9장 분석가 추천

행운의 수레바퀴
애널리스트의 견해
일관된 기회 맵

제10장 섹션

참고문헌
조사 방법

SHW

영문 목차

영문목차

Global Eosinophilic Esophagitis Market is estimated to be valued at USD 239.1 Mn in 2025 and is expected to reach USD 1,797.4 Mn by 2032, growing at a compound annual growth rate (CAGR) of 33.4% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 239.1 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	33.40%	2032 Value Projection:	USD 1,797.4 Mn

Figure. Eosinophilic Esophagitis Market Share (%), By Region 2025

Eosinophilic esophagitis is a chronic condition which is treated with the help of steroids and acid suppressants such as proton pump inhibitors. Steroids help control the inflammation. Topical steroids are administered as a inhaler or as a liquid. Oral steroids may be prescribed to treat people who have serious swallowing problems or weight loss. Proton pump inhibitors help with reflux symptoms and decrease inflammation.

Market Dynamics

Growing awareness regarding eosinophilic esophagitis leads to an increase in demand for treatment products. Thus, key market players are engaged in developing newer treatments and addressing the demand for EoE treatment products. For instance, Sanofi S.A. a global biopharmaceutical company engaged in conducting a phase 3 clinical trial for Dupixent (dupilumab) and is estimated to complete by 2024. Additionally, upcoming innovative products to improve the management of EoE are anticipated to drive the global market growth. For instance, in December 2021, Takeda Pharmaceutical Company Limited a Japanese multinational pharmaceutical company received a Complete Response Letter (CRL) for TAK-721 (budesonide oral suspension) from the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis. In June 2021, the U.S. FDA granted Orphan Drug Designation (ODD) for Etrasimod. Etrasimod had been investigated by Arena Pharmaceuticals, Inc. an American biopharmaceutical company. Moreover, an increase in the prevalence of eosinophilic esophagitis is likely boost the market growth. For instance, according to a study published in the Saudi Medical Journal in July 2018, eosinophilic esophagitis is an emerging disease and has an increasing incidence in children in Saudi Arabia.

Key features of the study:

This report provides an in-depth analysis of the global eosinophilic esophagitis market size (US$ Mn), and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global eosinophilic esophagitis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, strategies
Key companies covered as a part of this study include Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Limited, AstraZeneca Plc, Sanofi S.A., Arena Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Revolo Biotherapeutics, Allakos Inc., Bristol-Myers Squibb Co, Calypso Biotech, DBV Technologies, Landos Biopharma, Inc., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Quorum Innovations LLC, and Dr. Falk Pharma GmbH
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global eosinophilic esophagitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global eosinophilic esophagitis market

Detailed Segmentation:

Global Eosinophilic Esophagitis Market, By Drug Class:
- Corticosteroids
- Budesonide
- Jorveza
- Off-label budesonide
- Fluticasone
- Proton Pump Inhibitor (PPI)
- Omeprazole
- Esomeprazole
- Others
- Late Stage Pipeline Drugs
- Dupixent
- APT-1011
- Lirentelimab (AK002)
- Cendakimab
- Etrasimod
- TAK-721
- Omilancor (BT-11)
Global Eosinophilic Esophagitis Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Eosinophilic Esophagitis Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- GlaxoSmithKline plc
- Ellodi Pharmaceuticals
- EsoCap AG
- Teva Pharmaceutical Industries Ltd.
- Cipla Limited
- Sun Pharmaceutical Industries Limited
- AstraZeneca Plc
- Sanofi S.A.
- Arena Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Revolo Biotherapeutics
- Allakos Inc.
- Bristol-Myers Squibb Co
- Calypso Biotech
- DBV Technologies
- Landos Biopharma, Inc.
- Glenmark Pharmaceuticals
- Alkem Laboratories Ltd.
- Quorum Innovations LLC
- Dr. Falk Pharma GmbH

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Drivers
Restraints
Opportunities
Impact Analysis
Pipeline Analysis
Regulatory Scenario
Recent Product Approval/Launch
PEST Analysis
Epidemiology

4. Global Eosinophilic Esophagitis Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply and Demand Analysis
Key Developments

5. Global Eosinophilic Esophagitis Market, By Drug Class, 2020 - 2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
  - Budesonide
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
      - Jorveza
        
        1. Introduction
        2. Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
      - Off-label budesonide
        
        1. Introduction
        2. Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - Fluticasone
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
Proton Pump Inhibitor (PPI)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
  - Omeprazole
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - Esomeprazole
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - Others
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
Late Stage Pipeline Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
  - Dupixent
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - APT-1012
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - Lirentelimab (AK002)
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - Cendakimab
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - Etrasimod
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - TAK-721
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - Omilancor (BT-11)
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)

6. Global Eosinophilic Esophagitis Market, By Distribution Channel, 2020 - 2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)

7. Global Eosinophilic Esophagitis Market, By Region, 2020 - 2032, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2022 and 2029 (%)
- Y-o-Y Growth Analysis, For Regions, 2021-2032
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
  - U.K.
  - Germany
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Heat Map Analysis
Market Share Analysis
- Ellodi Pharmaceuticals.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Strategies
- EsoCap AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Strategies
- GlaxoSmithKline plc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Teva Pharmaceutical Industries Ltd
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Cipla Limited
- Sun Pharmaceutical Industries Limited
- AstraZeneca Plc
- Sanofi S.A.
- Arena Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Revolo Biotherapeutics
- Allakos Inc.
- Bristol-Myers Squibb Co
- Calypso Biotech
- DBV Technologies
- Landos Biopharma, Inc.
- Glenmark Pharmaceuticals
- Alkem Laboratories Ltd.
- Quorum Innovations LLC
- Falk Pharma GmbH

9. Analyst Recommendation

Wheel of Fortune
Analyst View
Coherent Opportunity Map

10. Section

References
Research Methodology
About Us and Sales Contact

한글목차

시장 역학

본 조사의 주요 특징

목차

제1장 조사의 목적과 전제조건

제2장 시장 전망

제3장 시장 역학, 규제, 동향 분석

제4장 세계의 호산구성 식도염 시장-코로나바이러스(COVID-19) 팬데믹의 영향

제5장 세계의 호산구성 식도염 시장, 약제 클래스별, 2020년-2032년

제6장 세계의 호산구성 식도염 시장, 유통 채널별, 2020년-2032년

제7장 세계의 호산구성 식도염 시장, 지역별, 2020년-2032년

제8장 경쟁 구도